labetalol has been researched along with Cardiovascular Pregnancy Complications in 113 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare pregnancy outcomes, accounting for allocated group, between methyldopa-treated and labetalol-treated women in the CHIPS Trial (ISRCTN 71416914) of 'less tight' versus 'tight' control of pregnancy hypertension." | 9.22 | Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. ( Asztalos, E; Gafni, A; Ganzevoort, JW; Gruslin, A; Helewa, M; Hutton, E; Koren, G; Lee, SK; Lee, T; Logan, AG; Magee, LA; Menzies, J; Moutquin, JM; Murphy, KE; Rey, E; Ross, S; Sanchez, J; Singer, J; Thornton, JG; von Dadelszen, P; Welch, R, 2016) |
| " Methyldopa, labetalol, and nifedipine have been perceived safe to use during pregnancy and are therefore recommended in international guidelines for treatment of hypertension." | 9.22 | Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. ( Allegaert, K; Flint, RB; Mian, P; Schoenmakers, S; van de Vusse, D; Versmissen, J; Visser, W, 2022) |
| "We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol." | 9.15 | Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. ( Baggio, MR; Berezowski, AT; Calderon, AC; Cavalli, RC; Duarte, G; Marcolin, AC; Martins, WP, 2011) |
| "Nicardipine and labetalol are effective and safe in the initial treatment of severe hypertension of pregnancy." | 9.10 | Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. ( Abroug, F; Boussarssar, M; Elatrous, S; Marghli, S; Nouira, S; Ouanes Besbes, L; Sakkouhi, M, 2002) |
| "We sought to compare the efficacies of oral nifedipine and intravenous labetalol in the acute management of hypertensive emergencies of pregnancy." | 9.09 | A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. ( Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH)." | 9.08 | Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. ( al-Fadly, A; el-Qarmalawi, AM; Hashem, M; Morsy, AH; Obeid, A, 1995) |
| "Anti-hypertensive intervention therapy in pregnancy induced hypertension has been examined using a placebo controlled randomised double-blind trial of labetalol in pregnancy." | 9.07 | A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1992) |
| "The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented." | 9.06 | Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ( Michael, CA, 1986) |
| "Labetalol was compared with methyldopa in a randomised trial involving 176 pregnant women with mild to moderate hypertension." | 9.06 | [Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial]. ( Bréart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1987) |
| "The effects of labetalol were compared with those of placebo in a multicentre randomized double-blind and prospective study of 152 patients with mild to moderate, non-proteinuric pregnancy-induced hypertension." | 9.06 | The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1989) |
| "Three hundred women with mild chronic hypertension at 6 to 13 weeks' gestation were randomly allocated to receive either methyldopa or labetalol or be in the control group." | 9.06 | A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. ( Anderson, GD; Mabie, WC; Shamsa, F; Sibai, BM; Villar, MA, 1990) |
| "Labetalol (Trandate; Allen & Hanburys), a combined alpha- and beta-adrenergic blocking agent, was compared with the more commonly used peripheral vasodilator, dihydrallazine (Nepresol; Ciba), each administered as an infusion, in the treatment of severe hypertension in 20 primigravidas at greater than or equal to 32 weeks' gestation." | 9.06 | Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. ( Ashe, RG; Moodley, J; Philpott, RH; Richards, AM, 1987) |
| "Labetalol was compared with methyldopa in a randomized controlled trial involving 176 pregnant women with mild to moderate hypertension." | 9.06 | Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. ( Breart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1988) |
| "Twentysix women with pregnancy-induced hypertension have been randomly treated with either labetalol or Aldomet." | 9.05 | Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension. ( Broughton Pipkin, F; Lamming, GD; Symonds, EM, 1980) |
| "Patients with acute pregnancy-related hypertension were randomized to treatment with 200 mg oral labetalol or 10 mg intramuscular hydralazine." | 9.05 | Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. ( Calder, AA; Greer, I; Walker, JJ, 1983) |
| "Oral nifedipine is recommended along with labetalol and hydralazine for treatment of severe hypertension during pregnancy by most authorities." | 8.93 | Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. ( Gupta, N; Kirubakaran, R; Pareek, P; Shekhar, S, 2016) |
| "The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase." | 7.79 | Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2013) |
| "Our report describes the outcome of a twin pregnancy in a woman who was maintained on tacrolimus after a living related renal transplant." | 7.70 | Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. ( Anderson, V; Baqi, N; Hidalgo, G; Kumar, A; Markell, MS; Piecuch, S; Singh, A; Vyas, S, 1999) |
| "Pharmacokinetic parameters of oral labetalol were studied in eight women with pregnancy-induced hypertension in the third trimester of pregnancy." | 7.68 | Labetalol pharmacokinetics in pregnancy-induced hypertension. ( Rogers, RC; Sibai, BM; Whybrew, WD, 1990) |
| "8 mg/kg of an intravenous bolus of labetalol on maternal and fetal hemodynamics was investigated in ten women with pregnancy-induced hypertension." | 7.68 | Single dose of labetalol in hypertensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms. ( Ekblad, UU; Erkkola, RU; Mäkinen, JI; Pirhonen, JP, 1991) |
| "The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1- to 2-day hospitalization period) during the third trimester of pregnancy who received the oral twice-daily doses of 150 to 450 mg." | 7.68 | Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. ( Echizen, H; Ishizaki, T; Minoura, S; Saotome, T; Sato, T; Terashi, K, 1993) |
| "We prospectively studied the effects of oral labetalol therapy in patients with moderate to severe pregnancy induced hypertension (PIH)." | 7.68 | Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome. ( Bjornsson, S; Calder, AA; Mahmoud, TZ, 1993) |
| "This study reports the results that were obtained in 56 cases of arterial hypertension in pregnancy solely by beta-blocking with Atenolol or Labetalol." | 7.66 | [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. ( Beauséjour, B; Blazquez, G; Faurie, C; Flouvat, B; Gérard, J; Lardoux, H; Rousset, D, 1983) |
| "1 Seven women with hypertension of pregnancy were given the combined alpha- and beta-adrenoceptor blocking drug labetalol (50 mg i." | 7.66 | Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy. ( Fredholm, BB; Hjemdahl, P; Lunell, NO; Nisell, H; Persson, B; Wager, J, 1981) |
| "1 Eighty-five women with severe hypertension complicating pregnancy were treated with oral labetalol (Trandate)." | 7.66 | The evaluation of labetalol in the treatment of hypertension complicating pregnancy. ( Michael, CA, 1982) |
| "Labetalol was given to women with hypertension of pregnancy in their last trimester to study its acute effect on circulation and metabolism." | 7.66 | Labetalol, a combined alpha- and beta-blocker, in hypertension of pregnancy. ( Fredholm, B; Hjemdahl, P; Lewander, R; Lunell, NO; Nisell, H; Nylund, L; Persson, B; Sarby, B; Wager, J, 1982) |
| "1 Labetalol pharmacokinetics and concentration-effect relationships following intravenous administration have been studied in 10 women during the last trimester of pregnancies complicated by hypertension, in seven of these women postpartum (when normotensive) and in 10 normotensive female volunteers." | 7.66 | Labetalol disposition and concentration-effect relationships during pregnancy. ( Butters, L; Fitzsimons, C; Kelman, AW; Reid, JL; Rubin, PC, 1983) |
| "The use of captopril in pregnancy has not previously been reported." | 7.66 | Management of severe hypertension in pregnancy by a combined drug regimen including captopril: case report. ( Millar, JA; Morrison, N; Wilson, PD, 1983) |
| "1 Labetalol, a hypotensive agent combining alpha- and beta-adrenoceptor antagonist properties, was used to treat severe hypertensive disease complicating pregnancy." | 7.66 | Use of labetalol in the treatment of severe hypertension during pregnancy. ( Michael, CA, 1979) |
| "Labetalol was well tolerated and no significant maternal toxicity was noted." | 6.67 | Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. ( Campbell, DM; Cruickshank, DJ; MacGillivray, I; Robertson, AA, 1992) |
| "02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645." | 6.66 | [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. ( Blazquez, G; Gérard, J; Lardoux, H; Leperlier, E, 1988) |
| " The duration of action also varied in the labetalol group, with the shortest duration occurring in those patients who required the highest dosage for BP control." | 6.66 | A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. ( Amon, E; Gonzalez, AR; Mabie, WC; Sibai, BM, 1987) |
| "This was a nested cohort study of women with chronic hypertension and a singleton pregnancy recruited to the PANDA (Pregnancy And chronic hypertension: NifeDipine vs lAbetalol as antihypertensive treatment) study at one of three UK maternity units." | 5.30 | Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study. ( Chappell, LC; Cruickshank, JK; Khalil, A; Mills, C; Myers, JE; Nelson-Piercy, C; Seed, PT; Watt-Coote, I; Webster, LM, 2019) |
| "Beta blockers are now widely used to treat hypertension during pregnancy." | 5.27 | [Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases]. ( Dubois, D; Klepper, A; Leboullenger, P; Petitcolas, J; Temperville, B, 1984) |
| " The average daily dosage was 144." | 5.27 | Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. ( Blazquez, G; Chouty, F; Flouvat, B; Gerard, J; Lardoux, H, 1983) |
| "To compare pregnancy outcomes, accounting for allocated group, between methyldopa-treated and labetalol-treated women in the CHIPS Trial (ISRCTN 71416914) of 'less tight' versus 'tight' control of pregnancy hypertension." | 5.22 | Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. ( Asztalos, E; Gafni, A; Ganzevoort, JW; Gruslin, A; Helewa, M; Hutton, E; Koren, G; Lee, SK; Lee, T; Logan, AG; Magee, LA; Menzies, J; Moutquin, JM; Murphy, KE; Rey, E; Ross, S; Sanchez, J; Singer, J; Thornton, JG; von Dadelszen, P; Welch, R, 2016) |
| " Methyldopa, labetalol, and nifedipine have been perceived safe to use during pregnancy and are therefore recommended in international guidelines for treatment of hypertension." | 5.22 | Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. ( Allegaert, K; Flint, RB; Mian, P; Schoenmakers, S; van de Vusse, D; Versmissen, J; Visser, W, 2022) |
| "We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol." | 5.15 | Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. ( Baggio, MR; Berezowski, AT; Calderon, AC; Cavalli, RC; Duarte, G; Marcolin, AC; Martins, WP, 2011) |
| "Nicardipine and labetalol are effective and safe in the initial treatment of severe hypertension of pregnancy." | 5.10 | Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. ( Abroug, F; Boussarssar, M; Elatrous, S; Marghli, S; Nouira, S; Ouanes Besbes, L; Sakkouhi, M, 2002) |
| "We sought to compare the efficacies of oral nifedipine and intravenous labetalol in the acute management of hypertensive emergencies of pregnancy." | 5.09 | A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. ( Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH)." | 5.08 | Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. ( al-Fadly, A; el-Qarmalawi, AM; Hashem, M; Morsy, AH; Obeid, A, 1995) |
| "Anti-hypertensive intervention therapy in pregnancy induced hypertension has been examined using a placebo controlled randomised double-blind trial of labetalol in pregnancy." | 5.07 | A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1992) |
| "The effects of labetalol were compared with those of placebo in a multicentre randomized double-blind and prospective study of 152 patients with mild to moderate, non-proteinuric pregnancy-induced hypertension." | 5.06 | The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. ( Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1989) |
| "Three hundred women with mild chronic hypertension at 6 to 13 weeks' gestation were randomly allocated to receive either methyldopa or labetalol or be in the control group." | 5.06 | A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. ( Anderson, GD; Mabie, WC; Shamsa, F; Sibai, BM; Villar, MA, 1990) |
| "Labetalol was compared with methyldopa in a randomized controlled trial involving 176 pregnant women with mild to moderate hypertension." | 5.06 | Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. ( Breart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1988) |
| "Labetalol was compared with methyldopa in a randomised trial involving 176 pregnant women with mild to moderate hypertension." | 5.06 | [Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial]. ( Bréart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1987) |
| "The results of a prospective trial to evaluate the use of diazoxide and labetalol given intravenously in the management of severe hypertensive disease in pregnancy are presented." | 5.06 | Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ( Michael, CA, 1986) |
| "Labetalol (Trandate; Allen & Hanburys), a combined alpha- and beta-adrenergic blocking agent, was compared with the more commonly used peripheral vasodilator, dihydrallazine (Nepresol; Ciba), each administered as an infusion, in the treatment of severe hypertension in 20 primigravidas at greater than or equal to 32 weeks' gestation." | 5.06 | Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. ( Ashe, RG; Moodley, J; Philpott, RH; Richards, AM, 1987) |
| "Patients with acute pregnancy-related hypertension were randomized to treatment with 200 mg oral labetalol or 10 mg intramuscular hydralazine." | 5.05 | Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. ( Calder, AA; Greer, I; Walker, JJ, 1983) |
| "Twentysix women with pregnancy-induced hypertension have been randomly treated with either labetalol or Aldomet." | 5.05 | Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension. ( Broughton Pipkin, F; Lamming, GD; Symonds, EM, 1980) |
| "The present evidence suggests similar efficacy between nifedipine, hydralazine and labetalol in the treatment of severe hypertension in pregnancy." | 4.98 | Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. ( Sequeira, RP; Sridharan, K, 2018) |
| "Oral nifedipine is recommended along with labetalol and hydralazine for treatment of severe hypertension during pregnancy by most authorities." | 4.93 | Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. ( Gupta, N; Kirubakaran, R; Pareek, P; Shekhar, S, 2016) |
| "Oral nifedipine, and possibly labetalol and methyldopa, are suitable options for treatment of severe hypertension in pregnancy/postpartum." | 4.90 | Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. ( Firoz, T; Gordon, R; MacDonell, K; Magee, LA; Payne, BA; Vidler, M; von Dadelszen, P, 2014) |
| " It has also been used intravenously in phaeochromocytoma, tetanus, clonidine withdrawal, and as an adjunct to halothane to produce hypotensive anaesthesia." | 4.76 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. ( Prichard, BN, 1984) |
| " The American College of Obstetricians and Gynecologists recommends that acute-onset, severe hypertension be treated with first line-therapy (intravenous labetalol, intravenous hydralazine or oral nifedipine) within 60 minutes to reduce risk of maternal morbidity and death." | 3.96 | Identification of factors associated with delayed treatment of obstetric hypertensive emergencies. ( Akerman, MB; Elsayad, A; Halpern, TA; Heiselman, CJ; Heo, HJ; Kantorowska, A; Muscat, JC; Sicuranza, GB; Vintzileos, AM, 2020) |
| "Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia." | 3.83 | Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. ( Bateman, BT; Desai, RJ; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Maeda, A; Mogun, H; Patorno, E; Seely, EW, 2016) |
| " Antenatally, her blood pressure was controlled with labetalol, and blood tests including serum creatinine were within normal limits for pregnancy." | 3.81 | Fulminant antenatal pulmonary oedema in a woman with hypertension and superimposed preeclampsia. ( Kubota-Sjogren, Y; Nelson-Piercy, C, 2015) |
| "The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase." | 3.79 | Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2013) |
| " In response to moderate hypertension the patient received intravenous labetalol hydrochloride 20 mg." | 3.73 | Inadvertent intrathecal injection of labetalol in a patient undergoing post-partum tubal ligation. ( Balestrieri, PJ; Blank, RS; Grubb, CT; Hamza, MS; Ting, PH, 2005) |
| "Transcranial Doppler (TCD) ultrasound was used to measure the blood velocity in the middle cerebral arteries (MCA) of eight pregnant patients with hypertension, before and after the administration of a 200 mg oral dose of labetalol." | 3.71 | Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas. ( Allen, JC; Belfort, MA; Dizon-Townson, D; Tooke-Miller, C; Varner, MA, 2002) |
| "In 21 pregnancies complicated by pregnancy-induced hypertension (PIH) which was treated by antihypertensive drugs (labetalol, nifedipine), fetal behavioural recordings (quiet state, C1F; active state, C2F; no coincidence, NOC) and Doppler measurements of blood flow velocity in the umbilical artery (UA) (resistance index, RI) were made on two occasions (27-32 and 33-36 weeks of gestation)." | 3.70 | Pregnancy-induced hypertension, antihypertensive drugs and the development of fetal behavioural states. ( Bruschettini, PL; Gazzolo, D; Russo, A; Santi, F; Scopesi, F; Visser, GH, 1998) |
| "Two infants with features of severe beta adrenergic blockade, pericardial effusions, and myocardial hypertrophy were born to mothers receiving long term treatment with oral labetalol for hypertension in pregnancy." | 3.70 | Adverse neonatal effects of maternal labetalol treatment. ( Crooks, BN; Deshpande, SA; Hall, C; Milligan, DW; Platt, MP, 1998) |
| "Our report describes the outcome of a twin pregnancy in a woman who was maintained on tacrolimus after a living related renal transplant." | 3.70 | Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. ( Anderson, V; Baqi, N; Hidalgo, G; Kumar, A; Markell, MS; Piecuch, S; Singh, A; Vyas, S, 1999) |
| "Forty eight neonates, born to mothers suffering from pregnancy induced hypertension and receiving labetalol for control of blood pressure, were studied for the possible adverse effects of the drug." | 3.68 | Effects of maternal labetalol on the newborn infant. ( Deorari, AK; Munshi, UK; Paul, VK; Singh, M, 1992) |
| "Pharmacokinetic parameters of oral labetalol were studied in eight women with pregnancy-induced hypertension in the third trimester of pregnancy." | 3.68 | Labetalol pharmacokinetics in pregnancy-induced hypertension. ( Rogers, RC; Sibai, BM; Whybrew, WD, 1990) |
| "The effect of intravenously-administered labetalol (1 mg/kg) on uterine and fetal hemodynamics and fetal cardiac function was studied in 13 women with pregnancy-induced hypertension." | 3.68 | Effect of labetalol infusion on uterine and fetal hemodynamics and fetal cardiac function. ( Jouppila, P; Räsänen, J, 1993) |
| "The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1- to 2-day hospitalization period) during the third trimester of pregnancy who received the oral twice-daily doses of 150 to 450 mg." | 3.68 | Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. ( Echizen, H; Ishizaki, T; Minoura, S; Saotome, T; Sato, T; Terashi, K, 1993) |
| "8 mg/kg of an intravenous bolus of labetalol on maternal and fetal hemodynamics was investigated in ten women with pregnancy-induced hypertension." | 3.68 | Single dose of labetalol in hypertensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms. ( Ekblad, UU; Erkkola, RU; Mäkinen, JI; Pirhonen, JP, 1991) |
| "We prospectively studied the effects of oral labetalol therapy in patients with moderate to severe pregnancy induced hypertension (PIH)." | 3.68 | Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome. ( Bjornsson, S; Calder, AA; Mahmoud, TZ, 1993) |
| " The mother had been treated with adequate doses of labetalol because of pregnancy-induced hypertension and her plasma concentration was found to be 89 micrograms/l one day after delivery." | 3.67 | Half-life of maternal labetalol in a premature infant. ( Geven, W; Haraldsson, A, 1989) |
| "The transfer of labetalol into human breast milk and amniotic fluid was studied in women with pregnancy hypertension." | 3.67 | Transfer of labetalol into amniotic fluid and breast milk in lactating women. ( Kulas, J; Lunell, NO; Rane, A, 1985) |
| "1 Labetalol, a hypotensive agent combining alpha- and beta-adrenoceptor antagonist properties, was used to treat severe hypertensive disease complicating pregnancy." | 3.66 | Use of labetalol in the treatment of severe hypertension during pregnancy. ( Michael, CA, 1979) |
| "The use of captopril in pregnancy has not previously been reported." | 3.66 | Management of severe hypertension in pregnancy by a combined drug regimen including captopril: case report. ( Millar, JA; Morrison, N; Wilson, PD, 1983) |
| "1 Seven women with hypertension of pregnancy were given the combined alpha- and beta-adrenoceptor blocking drug labetalol (50 mg i." | 3.66 | Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy. ( Fredholm, BB; Hjemdahl, P; Lunell, NO; Nisell, H; Persson, B; Wager, J, 1981) |
| "1 Eighty-five women with severe hypertension complicating pregnancy were treated with oral labetalol (Trandate)." | 3.66 | The evaluation of labetalol in the treatment of hypertension complicating pregnancy. ( Michael, CA, 1982) |
| "Labetalol was given to women with hypertension of pregnancy in their last trimester to study its acute effect on circulation and metabolism." | 3.66 | Labetalol, a combined alpha- and beta-blocker, in hypertension of pregnancy. ( Fredholm, B; Hjemdahl, P; Lewander, R; Lunell, NO; Nisell, H; Nylund, L; Persson, B; Sarby, B; Wager, J, 1982) |
| "1 Labetalol pharmacokinetics and concentration-effect relationships following intravenous administration have been studied in 10 women during the last trimester of pregnancies complicated by hypertension, in seven of these women postpartum (when normotensive) and in 10 normotensive female volunteers." | 3.66 | Labetalol disposition and concentration-effect relationships during pregnancy. ( Butters, L; Fitzsimons, C; Kelman, AW; Reid, JL; Rubin, PC, 1983) |
| "This study reports the results that were obtained in 56 cases of arterial hypertension in pregnancy solely by beta-blocking with Atenolol or Labetalol." | 3.66 | [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. ( Beauséjour, B; Blazquez, G; Faurie, C; Flouvat, B; Gérard, J; Lardoux, H; Rousset, D, 1983) |
| "Labetalol was well tolerated and no significant maternal toxicity was noted." | 2.67 | Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. ( Campbell, DM; Cruickshank, DJ; MacGillivray, I; Robertson, AA, 1992) |
| "Normal pregnancy is a complex and dynamic process that requires significant adaptation from the maternal system." | 2.66 | Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond. ( Doherty, A; Kingdom, JC; McLaughlin, K, 2020) |
| "02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645." | 2.66 | [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. ( Blazquez, G; Gérard, J; Lardoux, H; Leperlier, E, 1988) |
| " The duration of action also varied in the labetalol group, with the shortest duration occurring in those patients who required the highest dosage for BP control." | 2.66 | A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. ( Amon, E; Gonzalez, AR; Mabie, WC; Sibai, BM, 1987) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "The etiology of preeclampsia is still unknown." | 2.41 | Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers. ( Bolte, AC; Dekker, GA; van Geijn, HP, 2001) |
| "Hypertension in pregnancy has implications for both maternal and fetal welfare." | 2.37 | Hypertension in pregnancy. Pathophysiology and management. ( Lubbe, WF, 1984) |
| "Labetalol is a unique antihypertensive agent which is a competitive peripheral antagonist at both alpha- and beta-adrenoceptor sites." | 2.37 | Current status of labetalol, the first alpha- and beta-blocking agent. ( Kanto, JH, 1985) |
| "Hypertension in pregnancy is associated with increased cardiovascular risk." | 1.62 | Severe hypertension in pregnancy. ( Damodaram, M; Frise, C; Wiles, K, 2021) |
| "To assess the influence of intrauterine growth retardation on heart rate (HR) and HR variability during sleep, we performed polygraphic recordings in 10 small-for-gestational age (SGA) and 16 appropriate-for-gestational age (AGA) newborns." | 1.29 | Heart rate and heart rate variability during sleep in small-for-gestational age newborns. ( Clairambault, J; Curzi-Dascalova, L; Eiselt, M; Kauffmann, F; Médigue, C; Peirano, P; Spassov, L, 1994) |
| "Labetalol has been advocated to rapidly decrease blood pressure in preeclamptic women and to blunt the hemodynamic response to tracheal intubation." | 1.28 | Maternal and fetal effects of labetalol in pregnant ewes. ( Dewan, DM; Eisenach, JC; Mandell, G, 1991) |
| "Beta blockers are now widely used to treat hypertension during pregnancy." | 1.27 | [Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases]. ( Dubois, D; Klepper, A; Leboullenger, P; Petitcolas, J; Temperville, B, 1984) |
| " The average daily dosage was 144." | 1.27 | Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. ( Blazquez, G; Chouty, F; Flouvat, B; Gerard, J; Lardoux, H, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (40.71) | 18.7374 |
| 1990's | 21 (18.58) | 18.2507 |
| 2000's | 14 (12.39) | 29.6817 |
| 2010's | 27 (23.89) | 24.3611 |
| 2020's | 5 (4.42) | 2.80 |
| Authors | Studies |
|---|---|
| Wiles, K | 1 |
| Damodaram, M | 1 |
| Frise, C | 1 |
| van de Vusse, D | 1 |
| Mian, P | 1 |
| Schoenmakers, S | 1 |
| Flint, RB | 1 |
| Visser, W | 1 |
| Allegaert, K | 1 |
| Versmissen, J | 1 |
| Webster, LM | 2 |
| Reed, K | 1 |
| Myers, JE | 2 |
| Burns, A | 1 |
| Gupta, P | 1 |
| Patel, P | 1 |
| Wiesender, C | 1 |
| Seed, PT | 2 |
| Nelson-Piercy, C | 3 |
| Chappell, LC | 3 |
| Magee, LA | 7 |
| Singer, J | 4 |
| Lee, T | 3 |
| McManus, RJ | 1 |
| Lay-Flurrie, S | 1 |
| Rey, E | 4 |
| Myers, J | 1 |
| Logan, AG | 4 |
| von Dadelszen, P | 5 |
| Kantorowska, A | 1 |
| Heiselman, CJ | 1 |
| Halpern, TA | 1 |
| Akerman, MB | 1 |
| Elsayad, A | 1 |
| Muscat, JC | 1 |
| Sicuranza, GB | 1 |
| Vintzileos, AM | 1 |
| Heo, HJ | 1 |
| Doherty, A | 1 |
| McLaughlin, K | 1 |
| Kingdom, JC | 1 |
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Lee, MS | 1 |
| Mills, C | 1 |
| Watt-Coote, I | 1 |
| Khalil, A | 1 |
| Cruickshank, JK | 1 |
| Sridharan, K | 1 |
| Sequeira, RP | 1 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Lemoine, ER | 1 |
| Karumanchi, SA | 1 |
| Alexander, JM | 1 |
| Wilson, KL | 1 |
| Caicedo, A | 1 |
| Thewissen, L | 1 |
| Naulaers, G | 1 |
| Lemmers, P | 1 |
| van Bel, F | 1 |
| Van Huffel, S | 1 |
| Xie, RH | 1 |
| Guo, Y | 1 |
| Krewski, D | 1 |
| Mattison, D | 1 |
| Nerenberg, K | 1 |
| Walker, MC | 1 |
| Wen, SW | 1 |
| Firoz, T | 1 |
| MacDonell, K | 1 |
| Payne, BA | 1 |
| Gordon, R | 1 |
| Vidler, M | 1 |
| Vadhera, RB | 1 |
| Simon, M | 1 |
| Rolfes, L | 1 |
| de Swart-Ruijter, I | 1 |
| van Hunsel, F | 1 |
| Shi, Q | 1 |
| Leng, W | 1 |
| Yao, Q | 1 |
| Mi, C | 1 |
| Xing, A | 1 |
| Shekhar, S | 1 |
| Gupta, N | 1 |
| Kirubakaran, R | 1 |
| Pareek, P | 1 |
| Ross, S | 3 |
| Asztalos, E | 2 |
| Murphy, KE | 2 |
| Menzies, J | 2 |
| Sanchez, J | 2 |
| Gafni, A | 3 |
| Gruslin, A | 3 |
| Helewa, M | 3 |
| Hutton, E | 2 |
| Koren, G | 3 |
| Lee, SK | 3 |
| Ganzevoort, JW | 2 |
| Welch, R | 2 |
| Thornton, JG | 2 |
| Moutquin, JM | 3 |
| Clark, SM | 1 |
| Dunn, HE | 1 |
| Hankins, GD | 1 |
| Kubota-Sjogren, Y | 1 |
| Bateman, BT | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Seely, EW | 1 |
| Mogun, H | 1 |
| Maeda, A | 1 |
| Fischer, MA | 1 |
| Hernandez-Diaz, S | 1 |
| Huybrechts, KF | 1 |
| Asencio Moreno, A | 1 |
| Alamán Orbañanos, B | 1 |
| Moro Velasco, MC | 1 |
| Shafi, NA | 1 |
| Malik, A | 1 |
| Silverman, DI | 1 |
| Merino, JL | 1 |
| Espejo, B | 1 |
| Ferreiro, P | 1 |
| Bueno, B | 1 |
| Paraíso, V | 1 |
| Baggio, MR | 1 |
| Martins, WP | 1 |
| Calderon, AC | 1 |
| Berezowski, AT | 1 |
| Marcolin, AC | 1 |
| Duarte, G | 1 |
| Cavalli, RC | 1 |
| Dueñas-Garcia, OF | 1 |
| Koucký, M | 1 |
| Daskas, N | 1 |
| Crowne, E | 1 |
| Shield, JP | 1 |
| Elatrous, S | 1 |
| Nouira, S | 1 |
| Ouanes Besbes, L | 1 |
| Marghli, S | 1 |
| Boussarssar, M | 1 |
| Sakkouhi, M | 1 |
| Abroug, F | 1 |
| Belfort, MA | 2 |
| Tooke-Miller, C | 1 |
| Allen, JC | 1 |
| Dizon-Townson, D | 1 |
| Varner, MA | 1 |
| De Conti, F | 1 |
| Da Cortà, R | 1 |
| Del Monte, D | 1 |
| Catena, V | 1 |
| Berton, G | 1 |
| Mormino, P | 1 |
| Pecoraro, L | 1 |
| Piovesana, P | 1 |
| Stählin, P | 1 |
| Gremmelmaier, D | 1 |
| Balestrieri, PJ | 1 |
| Hamza, MS | 1 |
| Ting, PH | 1 |
| Blank, RS | 1 |
| Grubb, CT | 1 |
| Clark, SL | 1 |
| Sibai, B | 1 |
| Chan, S | 1 |
| Hewson, S | 1 |
| Kavuma, E | 1 |
| McKay, D | 1 |
| Ohlsson, A | 1 |
| Willan, AR | 1 |
| Hannah, ME | 1 |
| Smith, AM | 1 |
| Walker, H | 1 |
| Bonduelle, M | 1 |
| Greer, I | 2 |
| Calder, AA | 4 |
| Lardoux, H | 5 |
| Gerard, J | 5 |
| Blazquez, G | 5 |
| Flouvat, B | 3 |
| Lubbe, WF | 1 |
| Louis, WJ | 1 |
| McNeil, JJ | 1 |
| Drummer, OH | 1 |
| Prichard, BN | 2 |
| Riley, AJ | 1 |
| Broughton Pipkin, F | 4 |
| Symonds, EM | 4 |
| Lamming, GD | 3 |
| Jadoul, FA | 1 |
| Millar, JA | 1 |
| Wilson, PD | 1 |
| Morrison, N | 1 |
| Hammerle, AF | 1 |
| Dubois, D | 1 |
| Petitcolas, J | 1 |
| Temperville, B | 1 |
| Klepper, A | 1 |
| Leboullenger, P | 1 |
| Nylund, L | 3 |
| Lunell, NO | 5 |
| Lewander, R | 3 |
| Sarby, B | 2 |
| Thornström, S | 2 |
| Mamoun, I | 1 |
| Sarby, S | 1 |
| Woods, DL | 1 |
| Malan, AF | 1 |
| Walker, JJ | 3 |
| Chouty, F | 2 |
| Beauséjour, B | 1 |
| Faurie, C | 1 |
| Rousset, D | 1 |
| Rubin, PC | 1 |
| Butters, L | 1 |
| Kelman, AW | 1 |
| Fitzsimons, C | 1 |
| Reid, JL | 1 |
| Fredholm, B | 1 |
| Hjemdahl, P | 2 |
| Nisell, H | 2 |
| Persson, B | 2 |
| Wager, J | 2 |
| Michael, CA | 4 |
| Robertson, JI | 1 |
| Fredholm, BB | 1 |
| el-Qarmalawi, AM | 1 |
| Morsy, AH | 1 |
| al-Fadly, A | 1 |
| Obeid, A | 1 |
| Hashem, M | 1 |
| Spassov, L | 1 |
| Curzi-Dascalova, L | 1 |
| Clairambault, J | 1 |
| Kauffmann, F | 1 |
| Eiselt, M | 1 |
| Médigue, C | 1 |
| Peirano, P | 1 |
| Jouppila, P | 1 |
| Räsänen, J | 1 |
| Saotome, T | 1 |
| Minoura, S | 1 |
| Terashi, K | 1 |
| Sato, T | 1 |
| Echizen, H | 1 |
| Ishizaki, T | 1 |
| Mahmoud, TZ | 1 |
| Bjornsson, S | 1 |
| Morgan, MA | 1 |
| Silavin, SL | 1 |
| Dormer, KJ | 1 |
| Fishburne, BC | 1 |
| Fishburne, JI | 1 |
| Gazzolo, D | 1 |
| Visser, GH | 1 |
| Russo, A | 1 |
| Scopesi, F | 1 |
| Santi, F | 1 |
| Bruschettini, PL | 1 |
| Crooks, BN | 1 |
| Deshpande, SA | 1 |
| Hall, C | 1 |
| Platt, MP | 1 |
| Milligan, DW | 1 |
| Vyas, S | 1 |
| Kumar, A | 1 |
| Piecuch, S | 1 |
| Hidalgo, G | 1 |
| Singh, A | 1 |
| Anderson, V | 1 |
| Markell, MS | 1 |
| Baqi, N | 1 |
| Vermillion, ST | 1 |
| Scardo, JA | 1 |
| Newman, RB | 1 |
| Chauhan, SP | 1 |
| Bull, SB | 1 |
| Logan, A | 1 |
| Ito, A | 1 |
| Shimano, Y | 1 |
| Otsuka, Y | 1 |
| Kato, M | 1 |
| Usami, T | 1 |
| Takeuchi, O | 1 |
| Koyama, K | 1 |
| Morozumi, K | 1 |
| Sano, T | 1 |
| Fukazu, A | 1 |
| Kimura, G | 1 |
| Bolte, AC | 1 |
| van Geijn, HP | 1 |
| Dekker, GA | 1 |
| Hussein, M | 1 |
| Mooij, JM | 1 |
| Roujouleh, H | 1 |
| Rosenthal, T | 1 |
| Oparil, S | 1 |
| Symonds, EB | 1 |
| Richards, DA | 1 |
| Munshi, UK | 1 |
| Deorari, AK | 1 |
| Paul, VK | 1 |
| Singh, M | 1 |
| Pickles, CJ | 2 |
| Cruickshank, DJ | 2 |
| Robertson, AA | 1 |
| Campbell, DM | 2 |
| MacGillivray, I | 1 |
| Eisenach, JC | 1 |
| Mandell, G | 1 |
| Dewan, DM | 1 |
| Pirhonen, JP | 1 |
| Erkkola, RU | 1 |
| Mäkinen, JI | 1 |
| Ekblad, UU | 1 |
| Fairlie, FM | 2 |
| Harper, A | 1 |
| Murnaghan, GA | 1 |
| Sibai, BM | 4 |
| Mabie, WC | 3 |
| Shamsa, F | 1 |
| Villar, MA | 1 |
| Anderson, GD | 2 |
| Rogers, RC | 1 |
| Whybrew, WD | 1 |
| Haraldsson, A | 2 |
| Geven, W | 2 |
| Lavies, NG | 1 |
| Meiklejohn, BH | 1 |
| May, AE | 1 |
| Achola, KJ | 1 |
| Fell, D | 1 |
| Naden, RP | 1 |
| Redman, CW | 1 |
| Kanto, JH | 1 |
| Durando, C | 1 |
| Leidi, L | 1 |
| Margaria, E | 1 |
| Medaglia, M | 1 |
| Gessa, M | 1 |
| Maina, G | 1 |
| Ahokas, RA | 1 |
| Leperlier, E | 2 |
| Acciaro, E | 1 |
| Acciaro, L | 1 |
| La Scala, G | 1 |
| Giuseppini, S | 1 |
| Valentini, A | 1 |
| Plouin, PF | 2 |
| Breart, G | 2 |
| Maillard, F | 2 |
| Papiernik, E | 2 |
| Relier, JP | 2 |
| Gonzalez, AR | 1 |
| Amon, E | 1 |
| Ashe, RG | 1 |
| Moodley, J | 1 |
| Richards, AM | 1 |
| Philpott, RH | 1 |
| Rasmussen, K | 1 |
| Greer, IA | 1 |
| Forbes, CD | 1 |
| Kulas, J | 1 |
| Rane, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The CHIPS Trial (Control of Hypertension In Pregnancy Study)[NCT01192412] | 987 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| A Randomized Control Trial of Furosemide or Placebo With Usual Antihypertensives in the Antepartum Management of Severe Hypertension With Wide Pulse Pressure[NCT04615624] | Phase 3 | 65 participants (Actual) | Interventional | 2021-01-04 | Completed | ||
| Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET)[NCT00293735] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-06-30 | Withdrawn (stopped due to Lack of funding) | ||
| A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-hypertensive Medication and Controls[NCT00759278] | 0 participants (Actual) | Observational | 2008-08-31 | Withdrawn (stopped due to No participants) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pregnancy loss or NICU admission for greater than 48 hours, as recorded in the maternal and infant medical records immediately following the birth (or pregnancy loss), and then again after the mothers' and infants' discharge home. Supplemental information, about potential post-discharge maternal or neonatal morbidities in the 6 weeks following birth for the mother, or 28 days of life for the baby, will be obtained by contacting women at 6 weeks postpartum and/or from medical records. (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 155 |
| 'Tight' Control. | 150 |
"Serious maternal complications measured up to 6 weeks postpartum. Death or one or more life-threatening maternal complications:~Adverse neurological complications (stroke, eclampsia, and/or blindness), and/or~End-organ failure (uncontrolled hypertension, inotropic support, pulmonary oedema, respiratory failure, myocardial ischaemia/infarction, renal failure, coagulopathy, and/or transfusion)" (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 18 |
| 'Tight' Control. | 10 |
22 reviews available for labetalol and Cardiovascular Pregnancy Complications
| Article | Year |
|---|---|
Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; M | 2022 |
Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond.
Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retarda | 2020 |
Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials.
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Female; Headache; Humans; Hydralazine; Hy | 2018 |
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
Hypertensive emergencies of pregnancy.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Creatine; Diuretics; Emergency Medicine; Female; | 2013 |
Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review.
Topics: Administration, Oral; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension, Pregnancy- | 2014 |
Hypertensive emergencies in pregnancy.
Topics: Antihypertensive Agents; Eclampsia; Emergencies; Female; Humans; Hydralazine; Hypertension; Hyperten | 2014 |
Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy.
Topics: Administration, Oral; Antihypertensive Agents; Female; Humans; Hypertension; Infusions, Intravenous; | 2015 |
Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Cost-Benefit Anal | 2016 |
A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension, | 2015 |
[Current perspective of treating hypertension in pregnancy].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Female; Humans; Hypertension; Hypertension, Pregn | 2011 |
Cerebral hemodynamics in preeclampsia: cerebral perfusion and the rationale for an alternative to magnesium sulfate.
Topics: Anticonvulsants; Antihypertensive Agents; Cerebrovascular Circulation; Eclampsia; Female; Humans; La | 2006 |
Hypertension in pregnancy. Pathophysiology and management.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Captopril; Clon | 1984 |
Pharmacology of combined alpha-beta-blockade. I.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Biological Availability; Chemica | 1984 |
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Antihyp | 1984 |
Clinical pharmacology of labetalol in pregnancy.
Topics: Ethanolamines; Female; Fetus; Heart Rate; Humans; Hypertension; Infant, Newborn; Kidney; Labetalol; | 1981 |
The generalizability of trial data; a comparison of beta-blocker trial participants with a prospective cohort of women taking beta-blockers in pregnancy.
Topics: Adrenergic beta-Antagonists; Adult; Cohort Studies; Databases as Topic; Diabetes, Gestational; Femal | 2001 |
Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diureti | 2001 |
The effect of antihypertensive drugs on the fetus.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; An | 2002 |
Doppler flow velocimetry in hypertension in pregnancy.
Topics: Female; Fetus; Hemodynamics; Humans; Hypertension; Labetalol; Mass Screening; Nifedipine; Placenta; | 1991 |
Antihypertensive drugs in pregnancy.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Diazoxide; Diuretics; Female; Fetus; Humans; H | 1985 |
Current status of labetalol, the first alpha- and beta-blocking agent.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Biot | 1985 |
26 trials available for labetalol and Cardiovascular Pregnancy Complications
| Article | Year |
|---|---|
Quantifying adherence to antihypertensive medication for chronic hypertension during pregnancy.
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Chromatography, High Pressure Liquid; | 2019 |
Are blood pressure level and variability related to pregnancy outcome? Analysis of control of hypertension in pregnancy study data.
Topics: Adult; Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension; Hypertension, Pregnancy- | 2020 |
Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study.
Topics: Adult; Antihypertensive Agents; Birth Weight; Black People; Blood Pressure; Chronic Disease; Cohort | 2019 |
Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Decision-Making; Female; Humans; Hypertensi | 2016 |
Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnanc | 2016 |
Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial.
Topics: Acute Disease; Adult; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension; Labetalol; | 2011 |
Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Nicardipine; Pre-Eclampsia; | 2002 |
The Control of Hypertension In Pregnancy Study pilot trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Patient Sat | 2007 |
Antihypertensive therapy in pregnancy.
Topics: Atenolol; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Labetalol; Ma | 1983 |
Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared.
Topics: Ethanolamines; Female; Heart Rate; Humans; Hydralazine; Hypertension; Labetalol; Pregnancy; Pregnanc | 1983 |
Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension.
Topics: Adult; Blood Pressure; Creatinine; Ethanolamines; Female; Fetus; Humans; Hydralazine; Hypertension; | 1980 |
Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension.
Topics: Adult; Blood Pressure; Cesarean Section; Dose-Response Relationship, Drug; Drug Administration Sched | 1995 |
A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Blood Pressure; Calcium Channel Blockers; | 1999 |
Use of labetalol and methyldopa in pregnancy-induced hypertension.
Topics: Administration, Oral; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Injections, Intra | 1979 |
A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension.
Topics: Administration, Oral; Adult; Female; Gestational Age; Humans; Hypertension; Labetalol; Length of Sta | 1992 |
Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study.
Topics: Adult; Female; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy Complications; Pregnancy Compli | 1992 |
Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol.
Topics: Adult; Blood Flow Velocity; Blood Pressure; Female; Heart Rate; Heart Rate, Fetal; Hemodynamics; Hum | 1991 |
A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy.
Topics: Adult; Female; Humans; Hypertension; Infant Mortality; Infant, Newborn; Labetalol; Methyldopa; Pregn | 1990 |
Atenolol in essential hypertension during pregnancy.
Topics: Atenolol; Female; Fetal Growth Retardation; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy Co | 1990 |
The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Infant, Newborn; | 1989 |
Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial.
Topics: Adult; Clinical Trials as Topic; Female; Fetal Death; Fetus; Hemodynamics; Humans; Hypertension; Inf | 1988 |
[Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial].
Topics: Adult; Clinical Trials as Topic; Female; Humans; Hypertension; Labetalol; Methyldopa; Pregnancy; Pre | 1987 |
[Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol].
Topics: Acebutolol; Adult; Female; Heart Rate, Fetal; Humans; Hypertension; Hypoglycemia; Infant, Newborn; L | 1988 |
A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; H | 1987 |
Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy.
Topics: Adolescent; Adult; Birth Weight; Clinical Trials as Topic; Delivery, Obstetric; Diazoxide; Female; H | 1986 |
Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy.
Topics: Blood Pressure; Clinical Trials as Topic; Dihydralazine; Female; Heart Rate; Heart Rate, Fetal; Huma | 1987 |
65 other studies available for labetalol and Cardiovascular Pregnancy Complications
| Article | Year |
|---|---|
Severe hypertension in pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Labetalol; Pre-Eclampsia; Pre | 2021 |
Identification of factors associated with delayed treatment of obstetric hypertensive emergencies.
Topics: Administration, Intravenous; Administration, Oral; Adult; After-Hours Care; Antihypertensive Agents; | 2020 |
Committee Opinion No. 692 Summary: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Drug Administration Routes; E | 2017 |
Committee Opinion No. 692: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Drug Administration Routes; E | 2017 |
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
Oral regimen management of acute hypertension in pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Methyldopa; Nifedipine; Pregnancy; | 2019 |
Effect of maternal use of labetalol on the cerebral autoregulation in premature infants.
Topics: Arterial Pressure; Blood Pressure; Cerebrum; Female; Gestational Age; Homeostasis; Humans; Hypotensi | 2013 |
Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Female; Humans; Hypertension; Hypertens | 2013 |
Labetalol for hypertension during pregnancy and nipple pain.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Labetalol; Nipples; Pain; Pregnancy; P | 2014 |
Oral nifedipine or intravenous labetalol for severe hypertension?
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pra | 2016 |
Fulminant antenatal pulmonary oedema in a woman with hypertension and superimposed preeclampsia.
Topics: Adult; Antihypertensive Agents; Cesarean Section; Female; Follow-Up Studies; Humans; Hypertension; L | 2015 |
Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Cohort Studies; Female; Humans; Hypertension; Hy | 2016 |
[Anesthesia for the surgical removal of bilateral pheochromocytomas during the second trimester of pregnancy].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adult; Anesthesia, Epidural; Anesthesia, Gene | 2009 |
Management of Takayasu arteritis during pregnancy.
Topics: Adult; Angiography; Antihypertensive Agents; Cesarean Section; Diagnosis, Differential; Female; Gluc | 2009 |
[Pregnancy and advanced chronic kidney disease].
Topics: Ductus Arteriosus, Patent; Epilepsy; Female; Fetal Growth Retardation; Humans; Hyaline Membrane Dise | 2010 |
False-positive amphetamine toxicology screen results in three pregnant women using labetalol.
Topics: Amphetamine; Amphetamine-Related Disorders; Antihypertensive Agents; False Positive Reactions; Femal | 2011 |
Is labetalol really a culprit in neonatal hypoglycaemia?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Female; Humans; Hypertension; Hypoglycemia; In | 2013 |
Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2002 |
Left ventricular diastolic function in pregnancy-induced hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Diastole; Echocardiography, Doppler; Female; Humans; Hypertensio | 2003 |
[Pregnancy and hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cesarean Section; Diagnosis, | 2005 |
Inadvertent intrathecal injection of labetalol in a patient undergoing post-partum tubal ligation.
Topics: Adult; Analgesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; Antihypertensive Agents; Bupi | 2005 |
Beta-blockers for pregnancy hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Female; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy | 1983 |
Which beta-blocker in pregnancy-induced hypertension?
Topics: Atenolol; Birth Weight; Ethanolamines; Female; Humans; Hypertension; Infant, Newborn; Labetalol; Pre | 1983 |
Renin and aldosterone concentrations in pregnant essential hypertensives - a prospective study.
Topics: Adult; Aldosterone; Female; Humans; Hypertension; Labetalol; Methyldopa; Potassium; Pregnancy; Pregn | 1983 |
Management of severe hypertension in pregnancy by a combined drug regimen including captopril: case report.
Topics: Adult; Captopril; Drug Therapy, Combination; Female; Furosemide; Humans; Hypertension, Renovascular; | 1983 |
[New aspects in the therapy of pregnancy-induced hypertension].
Topics: Anesthesia, Epidural; Epoprostenol; Female; Fenoterol; Humans; Hypertension; Labetalol; Metoprolol; | 1983 |
[Treatment of arterial hypertension in the pregnant woman with labetalol. A propos of 24 cases].
Topics: Adult; Apgar Score; Birth Weight; Ethanolamines; Female; Fetus; Humans; Hypertension; Infant, Newbor | 1984 |
Labetalol for the treatment of hypertension in pregnancy. Pharmacokinetics and effects on the uteroplacental blood flow.
Topics: Ethanolamines; Female; Humans; Hypertension; Kinetics; Labetalol; Placenta; Pregnancy; Pregnancy Com | 1984 |
Uteroplacental blood flow in pregnancy induced hypertension.
Topics: Blood Flow Velocity; Blood Pressure; Dihydralazine; Female; Fetal Heart; Heart Rate; Humans; Hyperte | 1984 |
Side effects of labetalol in newborn infants.
Topics: Ethanolamines; Female; Humans; Hypertension; Infant, Newborn; Infant, Newborn, Diseases; Labetalol; | 1983 |
Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol.
Topics: Adolescent; Adult; Atenolol; Ethanolamines; Female; Fetus; Humans; Hypertension; Infant, Newborn; La | 1983 |
[Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol].
Topics: Adolescent; Adult; Atenolol; Delivery, Obstetric; Ethanolamines; Female; Fetal Heart; Fetal Monitori | 1983 |
Labetalol disposition and concentration-effect relationships during pregnancy.
Topics: Adolescent; Adult; Blood Pressure; Ethanolamines; Female; Humans; Hypertension; Injections, Intraven | 1983 |
Labetalol, a combined alpha- and beta-blocker, in hypertension of pregnancy.
Topics: Adult; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Labetalol; Placenta; Pregnancy; Pr | 1982 |
The evaluation of labetalol in the treatment of hypertension complicating pregnancy.
Topics: Ethanolamines; Female; Fetus; Humans; Hypertension; Kidney; Labetalol; Liver; Milk, Human; Placenta; | 1982 |
Labetalol: the nineteen-eighties.
Topics: Adrenal Gland Neoplasms; Anesthesia; Coronary Disease; Ethanolamines; Female; Humans; Hypertension; | 1982 |
Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.
Topics: Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Labetalol; Lipid Metabolism | 1981 |
Heart rate and heart rate variability during sleep in small-for-gestational age newborns.
Topics: Basal Metabolism; Birth Weight; Female; Fetal Growth Retardation; Gestational Age; Heart Rate; Human | 1994 |
Effect of labetalol infusion on uterine and fetal hemodynamics and fetal cardiac function.
Topics: Blood Pressure; Female; Fetal Heart; Hemodynamics; Humans; Hypertension; Infusions, Intravenous; Lab | 1993 |
Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis.
Topics: Adult; Apgar Score; Birth Weight; Blood Pressure; Drug Administration Schedule; Female; Gestational | 1993 |
Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome.
Topics: Adult; Female; Fetus; Humans; Labetalol; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy Complications | 1993 |
Effects of labetalol on uterine blood flow and cardiovascular hemodynamics in the hypertensive gravid baboon.
Topics: Animals; Female; Hemodynamics; Hypertension; Iliac Artery; Labetalol; Papio; Pregnancy; Pregnancy Co | 1993 |
Pregnancy-induced hypertension, antihypertensive drugs and the development of fetal behavioural states.
Topics: Antihypertensive Agents; Cohort Studies; Embryo, Mammalian; Embryonic and Fetal Development; Female; | 1998 |
Adverse neonatal effects of maternal labetalol treatment.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Cardiomegaly; Dobutamine; Dopamine; Dr | 1998 |
Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus.
Topics: Azathioprine; Cesarean Section; Cyclosporine; Fatal Outcome; Female; Graft Rejection; Humans; Hypert | 1999 |
A case of renovascular hypertension due to bilateral renal artery microaneurysm who succeeded in baby delivery.
Topics: Adrenergic beta-Antagonists; Adult; Aneurysm; Angiography; Female; Humans; Hypertension, Renovascula | 2001 |
Factor analysis, including antihypertensive medication, of the outcome of pregnancy in pregnancy-associated hypertension.
Topics: Antihypertensive Agents; Apgar Score; Cesarean Section; Comorbidity; Disease Susceptibility; Female; | 2001 |
Use of labetalol in the treatment of severe hypertension during pregnancy.
Topics: Adolescent; Adult; Amniotic Fluid; Birth Weight; Ethanolamines; Female; Fetal Blood; Humans; Hyperte | 1979 |
Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.
Topics: Administration, Oral; Anesthesia; Angina Pectoris; Catecholamines; Ethanolamines; Female; Hemodynami | 1979 |
The treatment of hypertension in pregnancy.
Topics: Adolescent; Adult; Anticonvulsants; Antihypertensive Agents; Bethanidine; Eclampsia; Female; Humans; | 1978 |
Effects of maternal labetalol on the newborn infant.
Topics: Asphyxia Neonatorum; Female; Fetal Growth Retardation; Humans; Hypertension; Hypoglycemia; Incidence | 1992 |
Maternal and fetal effects of labetalol in pregnant ewes.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Female; | 1991 |
Single dose of labetalol in hypertensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms.
Topics: Adult; Blood Flow Velocity; Blood Pressure; Female; Fetus; Heart Rate; Heart Rate, Fetal; Hemodynami | 1991 |
Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol.
Topics: Female; Heart Rate, Fetal; Hemodynamics; Humans; Hydralazine; Hypertension; Labetalol; Pregnancy; Pr | 1991 |
Labetalol pharmacokinetics in pregnancy-induced hypertension.
Topics: Adolescent; Adult; Amniotic Fluid; Female; Fetal Blood; Humans; Hypertension; Labetalol; Metabolic C | 1990 |
Severe adverse effects of maternal labetalol in a premature infant.
Topics: Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Labetalol; Maternal-Fetal Exchange; Pr | 1989 |
Half-life of maternal labetalol in a premature infant.
Topics: Adult; Female; Half-Life; Humans; Hypertension; Infant, Newborn; Infant, Premature; Labetalol; Male; | 1989 |
Hypertensive and catecholamine response to tracheal intubation in patients with pregnancy-induced hypertension.
Topics: Adult; Blood Pressure; Cesarean Section; Female; Heart Rate; Humans; Hypertension; Intubation, Intra | 1989 |
[Hypertension in pregnancy: proposed monitoring and therapy].
Topics: Adrenergic beta-Antagonists; Captopril; Diuretics; Female; Follow-Up Studies; Humans; Hydralazine; H | 1985 |
Labetalol does not decrease placental perfusion in the hypertensive term-pregnant rat.
Topics: Animals; Female; Genitalia, Female; Hemodynamics; Hypertension; Labetalol; Muscles; Placenta; Pregna | 1989 |
[Labetalol in the treatment of pregnancy arterial hypertension. 70 cases].
Topics: Adult; Female; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy Complications, Cardiovascular | 1986 |
[Therapeutic monitoring of hypertensive syndrome in pregnancy].
Topics: Adult; Female; Humans; Hypertension; Labetalol; Monitoring, Physiologic; Pregnancy; Pregnancy Compli | 1988 |
Fetal haemodynamics before and after treatment of maternal hypertension in pregnancy.
Topics: Blood Flow Velocity; Female; Fetus; Hemodynamics; Humans; Hypertension; Labetalol; Maternal-Fetal Ex | 1987 |
Platelet function in pregnancy induced hypertension following treatment with labetalol and low dose aspirin.
Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Platelets; Collagen; Dose-Response Relationship, Drug; | 1987 |
Transfer of labetalol into amniotic fluid and breast milk in lactating women.
Topics: Amniotic Fluid; Female; Humans; Hypertension; Labetalol; Lactation; Milk, Human; Pregnancy; Pregnanc | 1985 |